Cadila Healthcare said : "The global market for primary biliary cholangitis treatment is expected to grow at a CAGR of 36.3% from 2018 - 2026 and is expected to reach USD 10.8 bn by 2026 as per Coherent market insights,"

business-standard Wednesday, December 9, 2020 2:06:00 PM EAT

Cadila Healthcare said : "it has received permission to initiate the phase 1 clinical trial of ZYIL1, a novel oral small molecule NLRP3 inhibitor candidate. NLRP3 inflammasomes are involved in the inflammation process"

timesofindia Monday, December 7, 2020 10:49:00 AM EAT

Cadila Healthcare said : “We will study the safety, tolerability, pharmacokinetics and pharmacodynamics of ZYIL1 in this phase I clinical trial in healthy human volunteers. We are committed to developing these pioneering novel treatments to the clinic for the patients in need”

timesofindia Monday, December 7, 2020 10:49:00 AM EAT

Cadila Healthcare said ( about Cadila Healthcare ) : “it has successfully completed a phase 2 clinical trial in Covid-19 patients with its biological therapy, Pegylated Interferon alpha-2b, ‘PegiHep’... Based upon the results from its Phase 2 study, Zydus Cadila now plans to conduct a phase 3 clinical trial in India”

HindustanTimes Thursday, November 12, 2020 1:39:00 PM EAT

Cadila Healthcare said ( about Cadila Healthcare ) : "it has successfully completed a phase 2 clinical trial in COVID-19 patients with its biological therapy, Pegylated Interferon alpha-2b, 'PegiHep'... Based upon the results from its Phase 2 study, Zydus Cadila now plans to conduct a phase 3 clinical trial in India"

business-standard Thursday, November 12, 2020 10:53:00 AM EAT

Cadila Healthcare said : "Clinical and regulatory development of Desidustat in COVID-19 is being executed in Mexico by Avant Sant Research Center S.A. de C.V., a leading contract research organisation headquartered in Monterrey, Mexico,"

news-yahoo-in Wednesday, July 8, 2020 11:59:00 PM EAT

Cadila Healthcare said : "Clinical and regulatory development of Desidustat in COVID-19 is being executed in Mexico by Avant Santé Research Center S.A. de C.V., a leading contract research organisation headquartered in Monterrey, Mexico,"

economictimes Monday, July 6, 2020 9:43:00 AM EAT

Cadila Healthcare said : "Clinical and regulatory development of Desidustat in COVID-19 is being executed in Mexico by Avant Santé Research Center S.A.de C.V., a leading contract research organisation headquartered in Monterrey, Mexico,"

newindianexpress Monday, July 6, 2020 9:16:00 AM EAT

Cadila Healthcare said : “The antibodies produced by the vaccine were able to completely neutralise the wild type virus indicating the protective potential of the vaccine candidate,”

business-standard Saturday, July 4, 2020 2:53:00 AM EAT

Cadila Healthcare said : "The eventual outcome of the impact of the global heath pandemic may be different from those estimated as on the date of approval of these financial results and the Group will closely monitor any material changes to the economic environment and their impact of its business in the times to come"

business-standard Friday, June 19, 2020 4:11:00 PM EAT

Cadila Healthcare said : "The global market for primary biliary cholangitis treatment is expected to grow at a CAGR of 36.3% from 2018 - 2026 and is expected to reach USD 10.8 bn by 2026 as per Coherent market insights,"

business-standard Wednesday, December 9, 2020 2:06:00 PM EAT

Cadila Healthcare said : "it has received permission to initiate the phase 1 clinical trial of ZYIL1, a novel oral small molecule NLRP3 inhibitor candidate. NLRP3 inflammasomes are involved in the inflammation process"

timesofindia Monday, December 7, 2020 10:49:00 AM EAT

Cadila Healthcare said : “We will study the safety, tolerability, pharmacokinetics and pharmacodynamics of ZYIL1 in this phase I clinical trial in healthy human volunteers. We are committed to developing these pioneering novel treatments to the clinic for the patients in need”

timesofindia Monday, December 7, 2020 10:49:00 AM EAT

Cadila Healthcare said ( about Cadila Healthcare ) : “it has successfully completed a phase 2 clinical trial in Covid-19 patients with its biological therapy, Pegylated Interferon alpha-2b, ‘PegiHep’... Based upon the results from its Phase 2 study, Zydus Cadila now plans to conduct a phase 3 clinical trial in India”

HindustanTimes Thursday, November 12, 2020 1:39:00 PM EAT

Cadila Healthcare said ( about Cadila Healthcare ) : "it has successfully completed a phase 2 clinical trial in COVID-19 patients with its biological therapy, Pegylated Interferon alpha-2b, 'PegiHep'... Based upon the results from its Phase 2 study, Zydus Cadila now plans to conduct a phase 3 clinical trial in India"

business-standard Thursday, November 12, 2020 10:53:00 AM EAT

Cadila Healthcare said : "Clinical and regulatory development of Desidustat in COVID-19 is being executed in Mexico by Avant Sant Research Center S.A. de C.V., a leading contract research organisation headquartered in Monterrey, Mexico,"

news-yahoo-in Wednesday, July 8, 2020 11:59:00 PM EAT

Cadila Healthcare said : "Clinical and regulatory development of Desidustat in COVID-19 is being executed in Mexico by Avant Santé Research Center S.A. de C.V., a leading contract research organisation headquartered in Monterrey, Mexico,"

economictimes Monday, July 6, 2020 9:43:00 AM EAT

Cadila Healthcare said : "Clinical and regulatory development of Desidustat in COVID-19 is being executed in Mexico by Avant Santé Research Center S.A.de C.V., a leading contract research organisation headquartered in Monterrey, Mexico,"

newindianexpress Monday, July 6, 2020 9:16:00 AM EAT

Cadila Healthcare said : “The antibodies produced by the vaccine were able to completely neutralise the wild type virus indicating the protective potential of the vaccine candidate,”

business-standard Saturday, July 4, 2020 2:53:00 AM EAT

Cadila Healthcare said : "The eventual outcome of the impact of the global heath pandemic may be different from those estimated as on the date of approval of these financial results and the Group will closely monitor any material changes to the economic environment and their impact of its business in the times to come"

business-standard Friday, June 19, 2020 4:11:00 PM EAT